Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents

Published:2016-02-06 Issue:3 Volume:16 Page:347-364
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Martino Massimo,Festuccia Moreno,Fedele Roberta,Console Giuseppe,Cimminiello Michele,Gavarotti Paolo,Bruno Benedetto

Publisher

Informa Healthcare

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

http://www.tandfonline.com/doi/pdf/10.1517/14712598.2015.1130821

Reference140 articles.

1. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management

2. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. XII. Hodgkin lymphoma in older patients: challenges and opportunities to improve outcomes

4. Prognostic factors and treatment outcome in primary progressive Hodgkin lymphoma: a report from the German Hodgkin Lymphoma Study Group

5. New Prognostic Score Based on Treatment Outcome of Patients With Relapsed Hodgkin's Lymphoma Registered in the Database of the German Hodgkin's Lymphoma Study Group

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms;Marine Drugs;2021-08-27

2. Successful Desensitization to Brentuximab After Anaphylactic Shock;Journal of Investigational Allergology and Clinical Immunology;2018-10-22

3. Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma;Bone Marrow Transplantation;2017-06-05

4. New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?;Expert Opinion on Biological Therapy;2017-05-22

5. Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin era;Bone Marrow Transplantation;2017-01-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3